VeriMom임신 중 sulindac을 피해야 할까요? | VeriMom
Sulindac is an NSAID with human and animal evidence of fetal harm (e.g., fetal renal dysfunction/oligohydramnios and ductus arteriosus effects that are class warnings for NSAIDs) and is listed by some safety sources as suspected/known developmental hazard; therefore reproductive hazard is suspected (H361 level evidence from registrants/SDSs and clinical reports). Mechanism is demonstrated COX/prostaglandin inhibition with known placental/fetal effects. Topical cosmetic use would give negligible systemic exposure compared with oral dosing; therefore exposure from a cosmetic topical route is judged negligible for adults. (Sources: LactMed (NLM), StatPearls/NCBI review of NSAIDs in pregnancy, clinical/toxicology studies; SDSs listing H361).
ECHA regulatory hazard statements
- •H360
- •H361
What to use instead
Pregnancy-safe ingredients that serve a similar function:
FAQ
- sulindac은 임신 중 안전한가요?
- Sulindac is an NSAID with human and animal evidence of fetal harm (e.g., fetal renal dysfunction/oligohydramnios and ductus arteriosus effects that are class warnings for NSAIDs) and is listed by some safety sources as suspected/known developmental hazard; therefore reproductive hazard is suspected (H361 level evidence from registrants/SDSs and clinical reports). Mechanism is demonstrated COX/prostaglandin inhibition with known placental/fetal effects. Topical cosmetic use would give negligible systemic exposure compared with oral dosing; therefore exposure from a cosmetic topical route is judged negligible for adults. (Sources: LactMed (NLM), StatPearls/NCBI review of NSAIDs in pregnancy, clinical/toxicology studies; SDSs listing H361).
- sulindac은 모유 수유 중 안전한가요?
- Breastfeeding guidance (LactMed) advises avoidance or preference for alternatives because data are lacking and sulindac has a long half‑life and metabolites; systemic maternal exposure can transfer drug/metabolites to milk. Mechanism (COX inhibition/systemic distribution) is established. Topical cosmetic use would be expected to give negligible maternal systemic exposure, so direct exposure via milk from cosmetic use is expected to be negligible. (Sources: LactMed, NCBI reviews, SDSs).
- sulindac은 아기 피부에 안전한가요?
- No infant‑specific dermal toxicity data were found. Hazard and mechanism remain the same (suspected reproductive/developmental hazard via prostaglandin inhibition). For baby skin (0–3 yr) exposure score is increased by +1 relative to adult because infant skin barrier is immature and systemic absorption may be greater if measurable; although topical cosmetic use of sulindac is uncommon and absolute absorption is likely low, infant exposure via dermal application cannot be assumed negligible without formulation data. (Sources: LactMed, NCBI/StatPearls on NSAIDs; SDSs/EHS listings).
- VeriMom은 sulindac을 어떻게 평가하나요?
- VeriMom은 EU CosIng, ECHA 분류, PubMed 연구를 기반으로 sulindac을 27/100 (높은 위험)로 평가합니다.
- 임신 중 sulindac 대체 안전 성분은?
- 유사한 기능을 가진 알려진 위험이 없는 대체 성분 목록을 확인하세요.
모든 성분표를 2초 만에 확인
VeriMom 무료 다운로드 — 어떤 제품이든 스캔해 임신 중 안전 점수를 즉시 확인하세요.
의료 면책 조항
이 정보는 교육 목적으로만 제공되며 의학적 조언을 구성하지 않습니다. 안전 점수는 공개적으로 이용 가능한 데이터를 기반으로 하며 모든 위험을 반영하지 않을 수 있습니다. 임신 중 또는 수유 중 제품을 사용하기 전에 항상 의료 전문가와 상담하십시오.